BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Fifteen-year follow-up from the S0016 trial suggests that some patients with advanced-stage follicular lymphoma may be cured with standard chemoimmunotherapy, according to Dr. Jonathan W. Friedberg, ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Investigators analyzed OS and PFS for patients with follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/ prednisolone (CHOP ...

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.